Beranda › Mieloma Multipel › Kansas
Uji klinis Mieloma Multipel di Kansas
12 studi untuk Mieloma Multipel mencari peserta di lokasi di Kansas.
Kota di Kansas
Teks studi resmi (Bahasa Inggris)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Kansas City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07391657A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Kansas Cancer Center, Kansas City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07258511A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Kansas University Medical Center, Westwood
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05201781Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- The University of Kansas Cancer Center - Westwood, Westwood
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- University of Kansas, Westwood
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06980480MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Kansas City
- Ascentist Doctors' Hospital, Leawood
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Merriam
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Mercy Hospital Pittsburg, Pittsburg
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Wichita
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT07764978Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Instititute - South, Overland Park
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
Menerima pesertaFase 3
Semua usia · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT05561387Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of Kansas Clinical Research Center, Westwood
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT06433947Dari ClinicalTrials.gov, data diambil 4 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.